Serum uric acid and gout: From the past to molecular biology

Current Medical Research and Opinion

Volumn 29, Issue SUPPL.3, 2013, Pages 3-8

  Punzi, L ^a   So, A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Febuxostat; Gout; Uric acid; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CANAKINUMAB; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FEBUXOSTAT; INFLAMMASOME; INTERLEUKIN 1BETA; LEAD; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OLIVE OIL; PURINE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR 2; TRIAMCINOLONE ACETONIDE; URIC ACID;

ALCOHOL CONSUMPTION; CHILL; DIETARY INTAKE; DRUG EFFICACY; FATIGUE; FEVER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; LEAD BLOOD LEVEL; LEAD POISONING; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN INTAKE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVIAL FLUID; URIC ACID BLOOD LEVEL;

GOUT; HUMANS; RISK FACTORS; URIC ACID;

EID: 84876927096     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.790800     Document Type: Review

References (53)

1. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11 (Pubitemid 44641591)
2. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48(Suppl 2):ii9-14
3. Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7 (Pubitemid 39006641)
4. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136-41
5. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960-6 (Pubitemid 351956658)
6. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis 2009;68:1728-33
7. Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2012 Jun 26 [Epub ahead of print]
8. Wilk JB, Djousse L, Borecki I, et al. Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet 2000;106:355-9 (Pubitemid 30201286)
9. Krishnan E, Lessov-Schlaggar CN, Krasnow RE, et al. Nature versus nurture in gout: a twin study. Am J Med 2012;125:499-504
10. Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012;8:610-21
11. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9 (Pubitemid 47193550)
12. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009;48(Suppl 2):ii2-8
13. Smith EU, D?́az-Torné C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010;24:811-27
14. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12:223
15. Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006;33:1341-5 (Pubitemid 44026423)
16. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397-414 (Pubitemid 38339910)
17. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012;344:d8190
18. Choi HK, Curhan G. Soft drinks, fructose consumption and the risk of gout in men: prospective cohort study. BMJ 2008;336:309-12 (Pubitemid 351278368)
19. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103 (Pubitemid 38298989)
20. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81 (Pubitemid 38496489)
21. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2004;51:1023-9 (Pubitemid 39648198)
22. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005;52:283-9 (Pubitemid 40129260)
23. Villegas R, Xiang Y-B, Cai Q, et al. Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab Syndr Relat Disord 2010;8:263-70
24. Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012;71:1448-53
25. Azzini E, Polito A, Fumagalli A, et al. Mediterranean diet effect: an Italian picture. Nutr J 2011;10:125
26. Shadick NA, Kim R, Weiss S, et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000;27:1708-12 (Pubitemid 30462816)
27. Lin JL, Tan DT, Ho HH, et al. Environmental lead exposure and urate excretion in the general population. Am J Med 2002;113:563-8
28. Krishnan E, Lingala B, Bhalla V. Low-level lead exposure and the prevalence of gout: an observational study. Ann Intern Med 2012;157:233-41
29. Dalbeth N, Wong S, Gamble GD, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis 2010;69:1677-82
30. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med 2009;169:502-7
31. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men: a prospective study. Arthritis Rheum 2007;56:2049-55 (Pubitemid 47110404)
32. Mandell BF, Edwards NL, Sundy JS, et al. Preventing and treating acute gout attacks across the clinical spectrum: a round table discussion. Cleve Clin J Med 2010;77(Suppl 2):S2-25
33. Hamburger M, Baraf HS, Adamson TC, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sports Med 2011;39:98-123
34. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421
35. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim.
36. Grainger R, McLaughlin RJ, Harrison A, et al. Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with intercritical gout. Rheumatology (Oxford) 2012 Nov 30 [Epub ahead of print]
37. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011;4:39-49
38. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961;54:452-60
39. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41 (Pubitemid 43372104)
40. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65
41. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26 (Pubitemid 35007355)
42. Srinivasula SM, Poyet JL, Razmara M, et al. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 2002;277:21119-22 (Pubitemid 34952246)
43. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32
44. Bertazzo A, Punzi L, Bertazzolo N, et al. Tryptophan catabolism in synovial fluid of various arthropathies and its relationship with inflammatory cytokines. Adv Exp Med Biol 1999;467:565-70 (Pubitemid 32202203)
45. Scanu A, Oliviero F, Ramonda R, et al. Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor-1 in the resolution phase. Ann Rheum Dis 2012;71:621-4
46. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
47. Torres R, Macdonald L, Croll SD, et al. Hyperalgesia, synovitis, and multiple biomarkers of inflammation are suppressed by IL-1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009;68:1602-8
48. Joosten LA, Netea MG, Mylona E, et al. Engagement of fatty acids with Tolllike receptor 2 drives interleukin-1-production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010;62:3237-48
49. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327:296-300
50. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-17
51. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48
52. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76
53. Lasko B, Sheedy B, Hingorani V. RDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients. Arthritis Rheum 2009;60:S413-14